News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Breaking Down BTK Degraders in CLL

Nirav N. Shah, MD, MSHP

Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

July 7th 2026

Nirav N. Shah, MD, MSHP, discusses bexobrutideg and what the BTK degrader could bring to chronic lymphocytic leukemia management.

Image Credit: © TheWaterMeloonProjec - stock.adobe.com

Dr Shah on the Significance of DAYBreak CLL-201 and Bexobrutideg for the CLL Treatment Paradigm

ByNirav N. Shah, MD

July 7th 2026

Nirav N. Shah, MD, MSHP, discusses the design of DAYBreak CLL-201 and its potential importance for chronic lymphocytic leukemia management.